로딩 중…
지수 로딩 중…
Onconic Therapeutics
476060· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩15,560-0.26%
2026-10-07
Financials
Valuation Metrics
Onconic Therapeutics's Market Cap is ₩7065B. At end of 2025 it was ₩8877B. Ranked #391 of 2,419 in KR market (top 16%), #139 of 1,638 on KOSDAQ (top 8%), #43 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 706.55B KRW | KR#391/2,419 Sec#43/231 |
| Revenue | 82.17B KRW | KR#1,536/2,419 Sec#97/231 |
| Net Income | 24.25B KRW | KR#633/2,419 Sec#39/231 |
| Total Assets | 75.71B KRW | KR#1,965/2,419 Sec#162/231 |
| Net Assets | 72.04B KRW | KR#1,666/2,419 Sec#140/231 |
| Employees | 38 | KR#2,147/2,419 Sec#198/231 |
| Value | ||
| P/E | 29.13x | KR#1,284/2,419 Sec#79/231 |
| P/B | 9.81x | KR#2,342/2,419 Sec#206/231 |
| P/S | 8.60x | KR#2,237/2,419 Sec#156/231 |
| EV/EBITDA | 38.11x | KR#1,260/2,419 Sec#80/231 |
| FCF Yield | 1.57% | KR#1,080/2,419 Sec#73/231 |
| Profitability | ||
| ROE | 33.66% | KR#43/2,419 Sec#4/231 |
| ROA | 32.03% | KR#15/2,419 Sec#3/231 |
| Op. Margin | 21.06% | KR#148/2,419 Sec#16/231 |
| Revenue Growth | 259.82% | KR#25/2,419 Sec#7/231 |
| Financial Health | ||
| Debt Ratio | 5.09% | KR#37/2,419 Sec#12/231 |
| Total Debt | 0 KRW | KR—/2,419 Sec—/231 |
| FCF | 11.09B KRW | KR#690/2,419 Sec#39/231 |
| Cash | 47.05B KRW | KR#769/2,419 Sec#46/231 |
| Net Debt/EBITDA | -2.72x | KR#182/2,419 Sec#8/231 |
| Performance | ||
| 1Y Return | -4.54% | KR#1,558/2,419 Sec#122/231 |
| 1M Return | -4.48% | KR#1,724/2,419 Sec#177/231 |
| From 52W High | -46.16% | KR#1,304/2,419 Sec#103/231 |
| 1Y MDD | -63.84% | KR#1,694/2,419 Sec#143/231 |
| Trading | ||
| Volume | 128,595 shares | KR#714/2,419 Sec#85/231 |
| Trading Value | 2.01B KRW | KR#569/2,419 Sec#73/231 |
| Foreign Own. | 0.02% | KR#2,283/2,419 Sec#219/231 |
| Per Share | ||
| EPS | 534 KRW | KR#970/2,419 Sec#68/231 |
| BPS | 1,586 KRW | KR#2,178/2,419 Sec#186/231 |
Company Info
Onconic Therapeutics, Inc. operates as a biopharmaceutical enterprise, primarily dedicated to the discovery and advancement of novel therapeutic solutions. Its research and development initiatives principally focus on creating new medications for acid-related ailments and various oncological conditions. This company was established on May 7, 2020, and maintains its principal office in Seoul, South Korea.